Current treatment of vitiligo is still a great challenge, since most cases of vitiligo have variable re-pigmentation outcomes due to their unpredictable responses to existing therapeutic regimens. There is an urgent need to identify this re-pigmentation process and to develop novel therapies. This review illustrates the most current research and latest understanding of vitiligo skin re-pigmentation and related regulatory mechanisms. Literature was collected from PubMed until January 2020, using the search terms including "vitiligo," "re-pigmentation," "phototherapy," "narrow-band ultraviolet B, " "excimer," "fractional carbon dioxide laser," and "melanocyte stem cells." Literature was mainly derived from English articles. Article type was not limited. Emerging evidence suggests that patients with vitiligo present various re-pigmentation patterns following ultraviolet B phototherapy, which relies on different cell reservoirs from the perilesional margins and/or from uninvolved hair follicles to replenish functional melanocytes that are lost in vitiliginous skin. The following events are likely to be involved in this re-pigmentation process, including: 1) changes in the paracrine secretion and distribution of transforming growth factor-β1 in the bulge area and in the epidermis; 2) the enhanced transfer of dermal pro-melanogenic growth factors to the epidermis; and 3) the induction of a C-X-C motif chemokine ligand (CXCL) 12-enriched micro-environment that efficiently recruits CXCR4- or CXCR7-positive melanocytes. Ongoing studies on the cellular and molecular events underlying vitiligo re-pigmentation will help design new therapeutic strategies to improve treatment outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249724PMC
http://dx.doi.org/10.1097/CM9.0000000000000794DOI Listing

Publication Analysis

Top Keywords

skin re-pigmentation
8
re-pigmentation patterns
8
cellular molecular
8
molecular events
8
events involved
8
re-pigmentation process
8
vitiligo re-pigmentation
8
re-pigmentation
7
vitiligo
6
deciphering skin
4

Similar Publications

Background: Vitiligo is a chronic autoimmune disease manifested by depigmented patches of skin devoid of melanocytes. Baricitinib, a JAK inhibitor selectively targeting JAK1/2, has shown preliminary efficacy for vitiligo. We aimed to assess the efficacy and tolerability of combination therapy with baricitinib and narrowband UV-B (NB-UVB) to treat active nonsegmental vitiligo (NSV).

View Article and Find Full Text PDF
Article Synopsis
  • * A case study details a 77-year-old woman with essential thrombocytosis who, after 20 weeks on low-dose hydroxyurea, experienced an unexpected change in hair color from gray to dark brown, along with other skin changes.
  • * The patient's side effect was monitored without intervention since she was pleased with the new hair color, suggesting that hydroxyurea may have both therapeutic benefits and unexpected aesthetic effects due to melanocyte activation.
View Article and Find Full Text PDF

Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses.

Exp Dermatol

September 2024

Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine, New York, New York, USA.

Article Synopsis
  • A study assessed the efficacy and safety of ritlecitinib, a JAK3/TEC inhibitor, in treating nonsegmental vitiligo among patients with different skin types over 24 weeks, involving 247 patients with light skin and 117 with dark skin.
  • Results showed significant improvement in facial vitiligo scores after 24 weeks for both skin types, with a 15.2% change for light skin and 37.4% for dark skin, alongside continuous repigmentation through week 48.
  • Additionally, the study noted variations in immune response markers related to skin type, suggesting that dark-skinned patients may respond to the treatment faster than those with light skin
View Article and Find Full Text PDF

Background: There is still no certain effective treatment for vitiligo as a common chronic skin disorder characterized by depigmented patches and loss of skin melanocytes.

Objectives: This study evaluates the efficacy of oral silymarin combined with hair follicle transplantation compared to follicle transplantation alone in the treatment of refractory vitiligo.

Materials And Methods: Twenty refractory vitiligo patients were enrolled in this randomized controlled clinical trial, following up for 3 months.

View Article and Find Full Text PDF

The Effect of Fractional Carbon Dioxide Laser on Melanogenesis in Human Melanocytes and Vitiligo Mouse Models.

Clin Cosmet Investig Dermatol

August 2024

Graduate School of Clinical Medicine, Bengbu Medical College, Bengbu, 233030, People's Republic of China.

Introduction: Vitiligo is an acquired skin pigmentation disorder, the cause of which is poorly understood. Researchers in this field are dedicated to exploring novel treatments for achieving re-pigmentation.

Methods: Mice were randomly selected and divided into control, model, and model+laser groups.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!